

## Claims

1. A compound for use in the prevention of pre-eclampsia in a subject at risk of pre-eclampsia or for use in the treatment of a subject suffering from pre-eclampsia, wherein said compound is a complement inhibitor.  
5
2. A compound for use according to claim 1, wherein the complement inhibitor is: an antibody, an agent inhibiting Factor XII activity, an agent inhibiting Kallikrein activity, an agent inhibiting bradykinin activity and/or an agent inhibiting C1 esterase activity.  
10
3. A compound for use according to claim 1 or 2, wherein the complement inhibitor is a C1 esterase inhibitor.
4. A compound for use according to claim 4, wherein the C1 esterase inhibitor is an antibody.  
15
5. A compound for use according to claim 4, wherein the C1 esterase inhibitor is a plasma-derived C1 esterase inhibitor.
6. A compound for use according to claim 4, wherein the C1 esterase inhibitor is a recombinant C1 esterase inhibitor, such as a C1 esterase inhibitor having an amino acid sequence that is substantially identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor.  
20
7. A compound for use according to claim 4, wherein the recombinant esterase inhibitor is produced in a transgenic non-human mammal, such as a mouse, goat, bovine, sheep, porcine or an animal from the order *Lagomorpha*, such as a *Leporidae*, including a rabbit.  
25
8. A compound for use according to any one of claims 5 - 7, wherein the C1 esterase inhibitor has a modified carbohydrate structure as compared to human plasma-derived C1 esterase inhibitor.  
30
9. A compound for use according to claim 8, wherein the C1 esterase inhibitor has a reduced level of terminal sialic acid residues as compared to plasma derived C1 inhibitor, wherein said reduced level of terminal sialic acid residues preferably results in a plasma half-life of less than 6 hours.  
35
10. A compound for use according to any one of the preceding claims, wherein the compound is administered to the subject at least once a month, or at least once a week.

11. A compound for use according to any one of claims 5 – 10, wherein the compound is administered in a dose ranging from 25 units/kg body weight to 100 units/kg body weight per administration, or ranging from 50 units/kg body weight to 100 units/kg body weight per administration.
- 5
12. A compound for use according to any one of the preceding claims, wherein the subject is a pregnant mammal, preferably a pregnant human.
13. A compound for use according to any of the preceding claims, wherein the subject suffering from pre-eclampsia is suffering from early-onset pre-eclampsia (<34 weeks gestational age) or from late-onset pre-eclampsia (>34 weeks gestational age).
- 10
14. A compound for use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
- 15
15. A compound for use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.
- 20
16. A compound for use according to claim 14 or 15, wherein the measurement is performed using the method as described in WO9810791.

25

30